Impact Factor
2.73
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.81
1,512 total citations
h5-index
44
h5 depth signal
Cited share
21.5%
420 of 1,957
Total citations
1,512
Citation footprint
Metric signal
0.74
External metric anchor
Self-citation
3.8%
58 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
6,738
United Kingdom
331
Canada
324
Ukraine
300
China
222
Citing Fields of Research
Oncology
3,068
Breast Cancer
2,294
Liver & Colon Cancer
821
Genetics & Genomics
685
Prostate Cancer
630
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
14,390
Articles tracked across the journal lifetime
Indexed publication set
1,957
420 cited publications
Last 12 months
342
28.5 publications/month
Open access share
11.1%
38 OA publications in the last year
Leading citing country
United States
6,738 citing publications
Leading citing field
Oncology
3,068 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Nov./Dec. 1991-
v1n1,Nov./Dec. 1991-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Prostate Cancer
Liver & Colon Cancer
Genetics & Genomics
Issuing & Sponsoring Bodies
Contributor
American Association for Cancer Research
Contributor
American Society of Preventive Oncology
Broad Categories
Biochemistry
Epidemiology
Neoplasms
Breast Cancer
Palliative Care
Genetics & Genomics
Oncology
Liver & Colon Cancer
Prostate Cancer
MeSH Descriptors
Genetic Markers
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/1055-9965.epi-26-0753
Open DOI
Examining Rural-Urban Differences in Genomic Testing Use for Breast Cancer in Idaho, 2013–2022
Background: Oncotype DX RS is a 21-gene assay that can be used to guide treatment decisions regarding adjuvant chemotherapy for women diagnosed with early-stage, estrogen receptor positive, human epidermal growth factor receptor 2 negati...
02
DOI 10.1158/1055-9965.epi-26-0718
Open DOI
Gut microbiome-related plasma metabolites and risk of colorectal cancer
Background: Perturbations in gut microbiome composition and altered levels of related metabolites may be related to colorectal cancer (CRC). This study assessed whether pre-diagnostic, circulating, microbiome-related metabolite concentra...
03
DOI 10.1158/1055-9965.epi-26-0667
Open DOI
Body Roundness Index and Cancer Risk in Postmenopausal Women: Findings from the Women’s Health Initiative
Background Body Roundness Index (BRI) is an anthropometric measure that combines waist circumference and height. It reflects central adiposity more accurately than body mass index (BMI). Evidence linking BRI to long-term cancer risk, par...
04
DOI 10.1158/1055-9965.epi-26-0120
Open DOI
Large-scale association study identifies lung cancer susceptibility copy number variants and their potential functional role in genetic instability
Background: Genome-wide association studies (GWAS) have identified numerous lung cancer susceptibility loci based on single nucleotide polymorphisms (SNPs), yet a substantial proportion of heritability remains unexplained. We therefore e...
05
DOI 10.1158/1538-7755.disp26-c026
Open DOI
Abstract C026: Cancer history and rural residence as determinants of genetic cancer risk testing engagement among U.S. adults
Background: Cancer genetic testing for inherited cancer risks has gained increasing recognition as a valuable risk assessment and personalized screening tool for individuals with personal or family cancer histories. Persistent disparitie...
06
DOI 10.1158/1538-7755.disp26-c027
Open DOI
Abstract C027: Evaluating a community-centered training program to strengthen advocates’ readiness to promote clinical research participation
Introduction: Participation of underrepresented populations in clinical trials is vital for cancer research and care. The Community Scientist Advocate (CSA) program trains health leaders to improve research participation among ethnic min...
07
DOI 10.1158/1538-7755.disp26-c029
Open DOI
Abstract C029: A practice in community: The Multiple Myeloma Community Connect Program
Background: /Purpose: Multiple myeloma (MM) is an uncommon and complicated blood cancer. Advances in research over the last 20 years have created numerous treatment options but not all patient groups benefit. Black patients have an incid...
08
DOI 10.1158/1538-7755.disp26-c028
Open DOI
Abstract C028: Health related quality of life status among Black prostate cancer survivors
Introduction: Globally, Black men suffer the greatest prostate cancer (CaP) burden. This study evaluated health-related quality of life (HRQOL) among Black prostate cancer survivors (CaPS) and compared their HRQOL by stage. We used a val...
09
DOI 10.1158/1538-7755.disp26-c030
Open DOI
Abstract C030: Enhancing accrual of Native Hawaiian men into prostate cancer clinical trials through a multilevel intervention
Background: Native Hawaiian (NH) men face a disproportionate burden of genitourinary (GU) cancers, experiencing the highest prostate cancer mortality rate in Hawaii and one of the highest fatality rates in the United States. Despite this...
10
DOI 10.1158/1538-7755.disp26-c031
Open DOI
Abstract C031: Building capacity in Native communities: Community health representative training in cancer navigation
Patient navigation is an evidence-based cancer intervention to address barriers to cancer care for underserved populations. Navigation includes guidance and information to support screening, diagnostic follow-up, treatment barriers, and ...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 29, no. 12 (Dec. 2020).
Available also online.
Vol. 1, no. 1 (NOV-DEC 1991)19911202 Notice published Printed on acid-free paper